Development and commercialization of biopharmaceutical solutions for neurological and autoimmune conditions.
A
CSR Analysis score
The organization is among the top 5% of organizations with the most committed CSR positioning, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: February 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Basilea Pharmaceutica
B
Development and commercialization of innovative pharmaceutical products for severe and life-threatening bacterial and fungal infections.
Orphan Europe
B
Development and commercialization of drugs for rare diseases.
Initiatives identified among leaders
Émissions GES limitées en direct, indirectes majeures via partenaires.
“Basilea indique que ses émissions directes de gaz ...” - Basilea PharmaceuticaDéveloppement de programmes de responsabilité sociale
“Takeda développe des programmes de responsabilité ...” - Takedaprise d'engagement pour la protection de l'environnement et la responsabilité sociétale
“Orphan Europe prend des engagements pour la protec...” - Orphan Europe49% of similar organizations communicate on CSR issues
+1094 initiatives collected from 49 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports